News & Events

In the news

The quarterly scientific journal – September 2022

Clean Mails

Here is the last edition of our quaterly Clean Mails newsletter, having as main subject "Integrated solution for cell banking & characterization". To read about this and find out Clean Cells, Naobios and Biodextris' news or to receive our next editions, click here.

Save the date !

Congresses: meet our teams!

Teams at Clean Cells, Naobios and Biodextris are traveling the world to attend major conferences and congresses within the biotech sector. As leaders of the biopharma field, our mission and our drive at the Clean Biologics group are to remain both reachable and up-to-date with regards to the latest developments and innovations.

The quarterly scientific journal – May 2022

Clean Mails

Here is the last edition of our quaterly Clean Mails newsletter, having as main subject "GMP biomanufacturing in a BSL-3 suite". To read about this and find out Clean Cells, Naobios and Biodextris' news or to receive our next editions, click here.

The quarterly scientific journal

Clean Mails - March 2022

Here is the last edition of our quarterly Clean Mails newsletter, having as main subject: "Optimization and Validation of digital PCR assays". To read about this and find out Clean Cells, Naobios and Biodextris' news or to receive our next editions, click here.

The quarterly scientific journal

Clean Mails

Here is the last edition of our quarterly Clean Mails newsletter, having as main subject: "Drug development post-pandemic". To read about this and find out Clean Cells, Naobios and Biodextris' news or to receive our next editions, click here.

Happy new year !

Our teams wish you the best for 2022

2021 has been a year rich in projects and innovations for our group. A new Canadian acquisition but also a new CEO, a new building under construction and many more challenges for 2022.

Clean Mails

The importance of technical oversight (CMC) in drug development

Technical oversight brought by a Chemistry, Manufacturing and Controls Subject Matter Expert (CMC SME) is crucial to ensure acceptance with regulatory bodies and patient safety at every stage of GMP manufacturing and in association with CDMO services provided by the Clean Biologics group.

Press Release

Clean Cells invests over €13M in new biopharmaceutical production site

5,300 m2 new facility will quadruple analysis and production capacity, becoming largest site in Europe for biopharmaceuticals quality control services and production of cell banks for innovative drugs.